Understanding the phenotypes and endotypes of allergic disease have facilitated biologics' use as a targeted and stratified treatment approach. However, although studies have supported the effectiveness of biologics in treating allergic diseases, the heterogeneous nature of allergic diseases represents a challenge for this treatment. In addition, despite the significant advances, this field has many unmet needs.
This Research Topic aims to explore the current knowledge about biologics treatment for allergic diseases (asthma, chronic urticaria, atopic dermatitis, chronic rhinosinusitis with nasal polyposis, food allergy and EoE), as well as identifying the latest advances, development and future perspective on this topic and highlight unmet needs. A better understanding of biologics will improve the approach to prescribing biologics and patient selection for this treatment.
Suitable themes include but are not limited to:
? Identifying the underlying allergic disease immunological mechanisms targeted by biologics with a focus on type 2 inflammatory pathway.
? Predictors of response to each biologic (biomarkers and patient clinical variables).
? An algorithm for selecting the appropriate biologic for specific diseases and patients.
? To define responders to biologics from non-responders.
? Use of biologics as an adjuvant with allergen immunotherapy.
? Biologics for food allergy and eosinophilic esophagitis.
? Cost-effectiveness of biologics use.
? Optimal duration of biologics treatment.
? Direct comparison between biologics.
All manuscript types accepted by Frontiers in Allergy are welcome.
Understanding the phenotypes and endotypes of allergic disease have facilitated biologics' use as a targeted and stratified treatment approach. However, although studies have supported the effectiveness of biologics in treating allergic diseases, the heterogeneous nature of allergic diseases represents a challenge for this treatment. In addition, despite the significant advances, this field has many unmet needs.
This Research Topic aims to explore the current knowledge about biologics treatment for allergic diseases (asthma, chronic urticaria, atopic dermatitis, chronic rhinosinusitis with nasal polyposis, food allergy and EoE), as well as identifying the latest advances, development and future perspective on this topic and highlight unmet needs. A better understanding of biologics will improve the approach to prescribing biologics and patient selection for this treatment.
Suitable themes include but are not limited to:
? Identifying the underlying allergic disease immunological mechanisms targeted by biologics with a focus on type 2 inflammatory pathway.
? Predictors of response to each biologic (biomarkers and patient clinical variables).
? An algorithm for selecting the appropriate biologic for specific diseases and patients.
? To define responders to biologics from non-responders.
? Use of biologics as an adjuvant with allergen immunotherapy.
? Biologics for food allergy and eosinophilic esophagitis.
? Cost-effectiveness of biologics use.
? Optimal duration of biologics treatment.
? Direct comparison between biologics.
All manuscript types accepted by Frontiers in Allergy are welcome.
